Kim Smith-Whitley
Technik-/Wissenschafts-/F&E-Leiter bei GLOBAL BLOOD THERAPEUTICS, INC.
Profil
Kim Smith-Whitley is currently the Director at the Sickle Cell Disease Association of America, Inc. and the Executive VP, Head-Research & Development at Global Blood Therapeutics, Inc. Dr. Smith-Whitley holds a doctorate degree from George Washington University.
Aktive Positionen von Kim Smith-Whitley
| Unternehmen | Position | Beginn |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2021 |
| Sickle Cell Disease Association of America, Inc. | Direktor/Vorstandsmitglied | - |
Ausbildung von Kim Smith-Whitley
| George Washington University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| Sickle Cell Disease Association of America, Inc. |
